Stock 0VY I-MAB
Add to a list
To use this feature you must be a member
Log inSign up

News I-Mab BOERSE MUENCHEN

Equities

0VY

US44975P1030

Real-time BOERSE MUENCHEN
Other stock markets
 15:14:17 2024-06-27 EDT 		5-day change 1st Jan Change
1.58 EUR -2.47% Intraday chart for I-Mab -2.41% -2.99%
06-06 I-Mab Appoints Phillip Dennis as Chief Medical Officer CI
06-05 I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
AQ
I-Mab Appoints Phillip Dennis as Chief Medical Officer
CI
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers
MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
PR
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
CI
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
AQ
I-Mab to Participate at the Jefferies Global Healthcare Conference
PR
I-MAB Filed 2023 Annual Report on Form 20-F
PR
Verastem Names John Hayslip as Chief Medical Officer
MT
I-Mab Announces Chief Medical Officer Changes
CI
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
AQ
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
PR
I-Mab Completes Business Divestiture in China
MT
I-Mab Announces Closing of the Divestiture of Business Operations in China
PR
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.
CI
I Mab : Resignations of Director and Senior Management - Form 6-K
PU
I-Mab Announces Executive Resignation
CI
Piper Sandler Adjusts Price Target on I-Mab to $10 From $15, Maintains Overweight Rating
MT
Needham Cuts Price Target on I-Mab to $6 From $8, Maintains Buy Rating
MT
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMAB Stock
  4. 0VY Stock
  5. News I-Mab